Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Crawford

Showing results (151-160 of 190) with videos related to

Pageof 19
Sort By:
Muscle & Nerve|August 26, 2010
Compound muscle action potential and motor function in children with spinal muscular atrophyAga Lewelt, Kristin J Krosschell, Charles Scott, et al.
Frontiers in Neurology|August 6, 2024
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ studyThomas O Crawford, John W Day, Darryl C De Vivo, et al.
Plos One|May 5, 2012
Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical studyThomas O Crawford, Sergey V Paushkin, Dione T Kobayashi, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 17, 2015
Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophyNimrod Miller, Zhihua Feng, Brittany M Edens, et al.
JAMA Pediatrics|December 1, 2018
Clinical Subpopulations in a Sample of North American Children Diagnosed With Acute Flaccid Myelitis, 2012-2016Matthew J Elrick, Eliza Gordon-Lipkin, Thomas O Crawford, et al.
Annals of Clinical and Translational Neurology|May 30, 2019
Neurofilament as a potential biomarker for spinal muscular atrophyBasil T Darras, Thomas O Crawford, Richard S Finkel, et al.
Neurology|February 8, 2024
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ StudyThomas O Crawford, Basil T Darras, John W Day, et al.
Pediatric Pulmonology|June 29, 2010
Evaluation and management of pulmonary disease in ataxia-telangiectasiaSharon A McGrath-Morrow, W Adam Gower, Cynthia Rothblum-Oviatt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 9, 2021
Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseasesChristopher Grunseich, Nathan Sarkar, Joyce Lu, et al.
Plos One|September 3, 2010
SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophyKathryn J Swoboda, Charles B Scott, Thomas O Crawford, et al.
Pageof 19

Showing results (151-160 of 190) with videos related to

Sort By:
Pageof 19
Muscle & Nerve|August 26, 2010
Compound muscle action potential and motor function in children with spinal muscular atrophyAga Lewelt, Kristin J Krosschell, Charles Scott, et al.
Frontiers in Neurology|August 6, 2024
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ studyThomas O Crawford, John W Day, Darryl C De Vivo, et al.
Plos One|May 5, 2012
Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical studyThomas O Crawford, Sergey V Paushkin, Dione T Kobayashi, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 17, 2015
Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophyNimrod Miller, Zhihua Feng, Brittany M Edens, et al.
JAMA Pediatrics|December 1, 2018
Clinical Subpopulations in a Sample of North American Children Diagnosed With Acute Flaccid Myelitis, 2012-2016Matthew J Elrick, Eliza Gordon-Lipkin, Thomas O Crawford, et al.
Annals of Clinical and Translational Neurology|May 30, 2019
Neurofilament as a potential biomarker for spinal muscular atrophyBasil T Darras, Thomas O Crawford, Richard S Finkel, et al.
Neurology|February 8, 2024
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ StudyThomas O Crawford, Basil T Darras, John W Day, et al.
Pediatric Pulmonology|June 29, 2010
Evaluation and management of pulmonary disease in ataxia-telangiectasiaSharon A McGrath-Morrow, W Adam Gower, Cynthia Rothblum-Oviatt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 9, 2021
Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseasesChristopher Grunseich, Nathan Sarkar, Joyce Lu, et al.
Plos One|September 3, 2010
SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophyKathryn J Swoboda, Charles B Scott, Thomas O Crawford, et al.
Pageof 19